TAK 861
Alternative Names: TAK-861Latest Information Update: 12 Jul 2024
At a glance
- Originator Takeda
- Class Sleep disorder therapies; Small molecules
- Mechanism of Action Orexin receptor type 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Narcolepsy
- Preclinical Idiopathic hypersomnia